Decoy Therapeutics Inc. DCOY
Decoy Therapeutics Inc. (Nasdaq: DCOY) is an infectious disease drug developer. Its lead program, IMP3ACT Designable Multi-Antivirals (D-MAV) peptide conjugates, is in Pre-clinical for respiratory viruses. Its next catalyst on record is D-MAV (IMP3ACT): File IND (FDA) or CTA (EU equivalent) (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: D-MAV (IMP3ACT) — File IND (FDA) or CTA (EU equivalent) (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| seclidemstat (SP-2577) | MDS/CMML (MD Anderson-sponsored trial with azacytidine); Ewing sarcoma | small molecule | Phase 1 |
| D-MAV (IMP3ACT) | respiratory viral infections | protein/peptide | Pre-clinical |
| SP-3164 | oncology (targeted protein degrader; to be integrated into P-PROTACs) | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.